Treatment with fruquintinib (Fruzaqla) plus sintilimab (Tyvyt) led to a significant improvement in progression-free survival (PFS) compared with axitinib (Inlyta) or everolimus (Afinitor) in patients with advanced or metastatic renal cell…
Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy
